Loading...
XASXCC5
Market cap18mUSD
Dec 23, Last price  
0.02AUD
Name

LBT Innovations Ltd

Chart & Performance

D1W1MN
XASX:CC5 chart
P/E
P/S
23.80
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
26.51%
Rev. gr., 5y
33.25%
Revenues
1m
-41.09%
03,394,0971,868,0001,992,0003,776,000500,000842,0004,339,0003,991,0002,367,0007,726,000330,000951,000299,0001,162,0001,123,0002,128,0002,132,0001,256,000
Net income
-4m
L-83.40%
0965,338722,000337,0001,488,000-1,162,000-1,156,000531,000292,000321,0003,577,000-5,133,000-2,685,000-4,350,000-5,636,000-7,260,000-6,641,000-22,524,000-3,740,000
CFO
-4m
L+162.73%
0000000-2,069,0002,436,0003,048,0007,874,000-657,0001,325,000-807,000-1,855,000-2,673,000-4,949,000-1,398,000-3,673,000
Earnings
Feb 21, 2025

Profile

LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia, Switzerland, the United States, the United Kingdom, and Germany. The company offers MicroStreak, an automated culture-plate streaking and inoculation system; and Automated Plate Assessment System, a platform technology that automates culture-plate screening and interpretation. It also develops Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds; Automated Plate Assessment System Pharma, a technology that uses cutting-edge artificial intelligent image analysis algorithms to automatically detect microbial growth for environmental monitoring applications; and devices that can detect biofilms in the presence of mammalian tissue. The company was incorporated in 2004 and is headquartered in Adelaide, Australia.
IPO date
Jul 31, 2006
Employees
28
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,256
-41.09%
2,132
0.19%
2,128
89.49%
Cost of revenue
9,199
8,719
9,432
Unusual Expense (Income)
NOPBT
(7,943)
(6,587)
(7,304)
NOPBT Margin
Operating Taxes
(935)
1,641
(2,118)
Tax Rate
NOPAT
(7,008)
(8,228)
(5,186)
Net income
(3,740)
-83.40%
(22,524)
239.17%
(6,641)
-8.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,580
1,668
BB yield
-39.64%
-11.80%
Debt
Debt current
209
1,194
1,157
Long-term debt
4,434
3,629
3,130
Deferred revenue
1,436
1,631
Other long-term liabilities
31
237
234
Net debt
2,296
2,803
(420)
Cash flow
Cash from operating activities
(3,673)
(1,398)
(4,949)
CAPEX
(6)
(305)
(655)
Cash from investing activities
(6)
(305)
(1,241)
Cash from financing activities
4,006
935
(637)
FCF
(8,635)
(4,019)
(8,491)
Balance
Cash
2,347
2,020
2,788
Long term investments
1,919
Excess cash
2,284
1,913
4,601
Stockholders' equity
2,423
(105)
21,335
Invested Capital
3,363
3,624
21,255
ROIC
ROCE
EV
Common stock shares outstanding
938,428
471,249
435,809
Price
0.02
-50.00%
0.03
-61.54%
0.08
2.63%
Market cap
14,076
-0.43%
14,137
-58.41%
33,993
9.26%
EV
16,372
16,940
33,573
EBITDA
(7,943)
(3,291)
(4,373)
EV/EBITDA
Interest
388
470
104
Interest/NOPBT